Anna Bochyńska

Anna Bochyńska

Neurologist and Dentist

In 1986 she graduated from the Faculty of Medicine and in 1988 she graduated from the Department of Dentistry at the Medical University in Poznań.

Since 1991 she has been working at the Institute of Psychiatry and Neurology in Warsaw where in 1997 she has obtained 2nd degree specialisation in Neurology, while in 2000 she obtained the title of Doctor of Medicine.

Currently she is an Assistant Professor at the 1st Neurology Clinic IPiN; for many years she is a member of the Scientific Council of the Institute. Licenced electroencephalography technician (EEG), member of the Polish Neurology Society, Polish Epileptology Society, Polish Society of Clinical Neurophysiology.

Her field of interest is epilepsy, stroke, Alzheimer’s disease. She participated and still participates in numerous scientific projects and clinical studies in the country and abroad.

Participation in clinical trials:

2006-2008 Trail NO 1175 Protocal RPCE04P 1901 UCB Pharma (LVE)

2005-2006 SITS-MOST

2006-2010 IST-3

2008-2013 INTERSTROKE

2008-2010 SCAST

2009-2012 DIAS-3

2014-2015 SOCRATES

2016-1017- GWEP 1330

Connect
Connect trials
Recruiting
Phase iii

ATLAS study

Industry trial

Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of ALS but do carry a certain superoxide dismutase 1 (SOD1) gene variant.

Read more
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Recruiting
Phase iii

ADORE Trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more